CTLA4 and lymphoma: No ICI in vivo/Anti-CTLA-4 mAb (Ipilimumab)/anti-PD-1 mAb (anti-hCD279, clone J116 BioXcell)/3× weekly (100 μg i.p.), starting 5–10 days after cell transfer until 4 weeks after cell transfer/Control huIgGICI applied in vitro reduced lymphomas as single therapies (P=0.06) or combination (P=0.03)/combination, lowered # latently, and lyrically infected B cells, increased EBV-specific T cell responsesICI considered useful for treating EBV-induced diseases